← Center for Biological Diversity
EPANonrulemakingEPA-HQ-OPP-2023-0445

Soliciting Feedback on a Proposed Regulatory Framework to Assess the Risk to the Effectiveness of Human and Animal Drugs Posed by Certain Antibacterial or Antifungal Pesticides

RIN
—
Last modified
Oct 10, 2024
Comment window
closed 712d ago
Center for Biological Diversity filings
2

Activity

Center for Biological Diversity filed 2 comments on this docket between Dec 19, 2023 and Aug 16, 2024. 18 other organizations filed here. The comment window closed 712d ago.

What Center for Biological Diversity filed (2)

Aug 16, 2024· Comment submitted by Center for Biological Diversity et al.· EPA-HQ-OPP-2023-0445-0098

Please find the attached comments of Center for Biological Diversity, Consumer Reports, Earthjustice, Food Animal Concerns Trust, HEAL (Health, Environment, Agriculture, Labor) Food Alliance, and The Public Interest Network on the Draft White Paper: Framework for Interagency Collaboration to Review Potential Antibacterial and Antifungal Resistance Risks Associated with Pesticide Use (Docket # EPA-HQ-OPP-2023-0445).

View on regulations.gov →
Dec 19, 2023· Comment submitted by Center for Biological Diversity et al.· EPA-HQ-OPP-2023-0445-0065

Please see attached comments from Center for Biological Diversity, Earthjustice, Food Animal Concerns Trust, Farmworker Association of Florida, Center for Food Safety, Health Care Without Harm, Center for Energy & Environmental Education at University of Northern Iowa, Antibiotic Resistance Action Center (ARAC) at the Milken Institute School of Public Health at George Washington University, Pesticide Action Network, Family Farm Defenders, Toxic Free North Carolina

Download attachment ↓View on regulations.gov →

Abstract

The U.S. Environmental Protection Agency (EPA) is soliciting feedback on the development of a framework to improve assessments of potential risks to human and animal health where the use of certain pesticides could potentially result in antimicrobial resistance that compromises the effectiveness of medically important antibacterial and antifungal drugs. The framework is being developed through a U.S. government interagency process with the U.S. Environmental Protection Agency (EPA), the U.S. Department of Health and Human Services (HHS), and the U.S. Department of Agriculture (USDA), under the oversight of the White House Executive Office of the President.

View on regulations.gov →

Co-filers (18)

See everyone who commented →